[Long-term treatment using Arwin of patients with chronic peripheral arterial blood circulation disorders].
D000368:Aged; D000787:Angina Pectoris / Q000209:etiology; D000818:Animals; D001162:Arteriosclerosis Obliterans / Q000150:complications / Q000188:drug therapy*; D002561:Cerebrovascular Disorders / Q000139:chemically induced; D002908:Chronic Disease; D004341:Drug Evaluation; D057487:Enzyme Therapy; D004798:Enzymes / Q000009:adverse effects; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006460:Hemolysin Proteins / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008296:Malaysia; D011247:Pregnancy; D012911:Snakes; D013045:Species Specificity; D013997:Time Factors; D014688:Venoms
D004798:Enzymes; D006460:Hemolysin Proteins; D014688:Venoms
Langzeitbehandlung mit Arwin bei Patienten mit chronischen peripheren arteriellen Durchblutungssetörungen